Skip to main content
. Author manuscript; available in PMC: 2014 Jun 15.
Published in final edited form as: Cancer Res. 2013 Apr 10;73(12):3671–3682. doi: 10.1158/0008-5472.CAN-12-4453

Figure 6. Inhibition of Pak or β-catenin impedes the tumorigenicity of ErbB2 positive breast cancer cells.

Figure 6

BT-474 cells were injected into the flanks of C.B17/IcrSCID mice. Ten days post-innoculation, the animals were treated with vehicle or inhibitors for 15 days. (A and B) Volumetric changes in tumor size between untreated mice (vehicle) and mice treated with inhibitors. (C) Average tumor size of untreated mice (vehicle) and mice treated with inhibitors. (D) Quantification of relative difference in activation of the indicated proteins between the different drug treatments. Each bar represents percent of inhibition relative to the controls. Data derived from immunoblots from 5 mice per antibody. Bars, SD. *p<0.05. (E) Representative example of tumor sections between untreated mice and mice treated with Pak inhibitor, β-catenin inhibitor and a combination of Pak and β-catenin inhibitors stained for cleaved caspase-3 and Ki67.